Hubei Biocause Heilen Pharmaceutical Co (SZSE:301211) YoY EBITDA Growth : -8.33% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Hubei Biocause Heilen Pharmaceutical Co YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Hubei Biocause Heilen Pharmaceutical Co's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was -8.33%.

Hubei Biocause Heilen Pharmaceutical Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.15.

Hubei Biocause Heilen Pharmaceutical Co YoY EBITDA Growth Historical Data

The historical data trend for Hubei Biocause Heilen Pharmaceutical Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hubei Biocause Heilen Pharmaceutical Co YoY EBITDA Growth Chart

Hubei Biocause Heilen Pharmaceutical Co Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

85.39

-10.54

-26.83

-19.76

31.37

Hubei Biocause Heilen Pharmaceutical Co Quarterly Data
	Dec18	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial															147.06	646.15	248.65	-71.50	-8.33

Hubei Biocause Heilen Pharmaceutical Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Hubei Biocause Heilen Pharmaceutical Co's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(0.779	-	0.593)	/	\| 0.593 \|
=	31.37 %

Hubei Biocause Heilen Pharmaceutical Co's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(0.154	-	0.168)	/	\| 0.168 \|
=	-8.33 %

Hubei Biocause Heilen Pharmaceutical Co YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Hubei Biocause Heilen Pharmaceutical Co's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Hubei Biocause Heilen Pharmaceutical Co (SZSE:301211) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hubei Biocause Heilen Pharmaceutical Co Ltd (SZSE:301211) » Definitions » YoY EBITDA Growth

Traded in Other Exchanges

N/A

Address

No. 122, Yangwan Road, Dadao District, Jingmen High-tech Zone, Hubei Province, Jingmen, CHN, 448000

Website

http://www.biocause.com

Hubei Biocause Heilen Pharmaceutical Co Ltd is engaged in the research and development, production and sales of chemical raw materials and preparation products.

Hubei Biocause Heilen Pharmaceutical Co (SZSE:301211) Headlines

No Headlines